Replimune Group Inc (REPL)

$10.09 +0.37 (3.81%)
Market Cap 762.47M
Revenue (ttm) 0.00
Net Income (ttm) -247.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.18
Volume 607,000
Avg Vol 4,522,622
Day's Range N/A - N/A
Shares Out 78.44M
Stochastic %K 75%
Beta 0.66
Analysts Strong Sell
Price Target $12.57

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 222 9600
Address:
500 Unicorn Park Drive, Suite 303, Woburn, United States
UgoGreg
UgoGreg Dec. 21 at 9:04 PM
$REPL https://stocktwits.com/symbol/CRDF
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Dec. 19 at 4:06 PM
$REPL pdufa in several months but the market super competitive for melanoma
0 · Reply
Doplrshift
Doplrshift Dec. 16 at 9:00 PM
$REPL this one might be in for a massive drop after that close
0 · Reply
Doplrshift
Doplrshift Dec. 16 at 8:55 PM
$REPL is this the lowest close for this stock since before thanksgiving
0 · Reply
Doplrshift
Doplrshift Dec. 16 at 8:51 PM
$REPL and so is the stock today
0 · Reply
BigTree79
BigTree79 Dec. 16 at 12:26 PM
$REPL wow this board is dead
0 · Reply
ItTakesItAll
ItTakesItAll Dec. 9 at 1:32 PM
$REPL 280%+ 2.79-10.73🎈 The ultimate 6-month ROI? Last July, I spotted and capitalized on a perfect market distortion from an overreaction. That generated a stunning 185%+ ROI by July 2025, a growth story still flourishing six months later. Stop accepting the norm, break free, block out the noise, and genuinely live.
1 · Reply
Dorps332
Dorps332 Dec. 8 at 2:45 PM
$IOVA guess it’s better to have a non approved treatment like $REPL then to have a working approved treatment like ourself
2 · Reply
Stock_Catcher
Stock_Catcher Dec. 5 at 3:44 AM
Fortune Friday Watchlist Pt. 10 $ETHZ $HUBC $REPL $JFBR $PTN Let's Bank Tomorrow ✅
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 4 at 4:48 PM
$REPL Share Price: $10.47 Contract Selected: Dec 26, 2025 $10 Calls Buy Zone: $0.47 – $0.58 Target Zone: $0.87 – $1.06 Potential Upside: 76% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on REPL
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 7 days ago

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

The Short List — Top 10 Most Shorted Stocks Right Now

Nov 26, 2025, 11:34 AM EST - 4 weeks ago

The Short List — Top 10 Most Shorted Stocks Right Now

ATYR CMBM HIMS HTZ LCID NTLA SOC

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Nov 7, 2025, 4:45 PM EST - 6 weeks ago

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Nov 6, 2025, 8:00 AM EST - 7 weeks ago

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Oct 20, 2025, 7:00 AM EDT - 2 months ago

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Oct 19, 2025, 8:00 AM EDT - 2 months ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Sep 21, 2025, 7:40 AM EDT - 3 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Replimune Provides Update Following Type A Meeting with FDA

Sep 18, 2025, 9:15 AM EDT - 3 months ago

Replimune Provides Update Following Type A Meeting with FDA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Sep 13, 2025, 10:10 AM EDT - 3 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Sep 5, 2025, 6:54 PM EDT - 3 months ago

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Sep 2, 2025, 9:46 PM EDT - 4 months ago

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Replimune Announces Type A Meeting Scheduled with FDA

Sep 2, 2025, 8:00 AM EDT - 4 months ago

Replimune Announces Type A Meeting Scheduled with FDA

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

Aug 13, 2025, 4:39 PM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Aug 13, 2025, 3:26 PM EDT - 4 months ago

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Replimune Group: The Prospects For FDA Approval After Rejection

Aug 7, 2025, 10:08 AM EDT - 5 months ago

Replimune Group: The Prospects For FDA Approval After Rejection

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:00 AM EDT - 5 months ago

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Why Is Replimune Stock Trading Lower On Monday?

Aug 4, 2025, 12:43 PM EDT - 5 months ago

Why Is Replimune Stock Trading Lower On Monday?

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Aug 1, 2025, 10:51 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

Jul 30, 2025, 8:36 AM EDT - 5 months ago

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Jul 28, 2025, 8:36 AM EDT - 5 months ago

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jul 25, 2025, 5:04 PM EDT - 5 months ago

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

Jul 24, 2025, 8:07 AM EDT - 5 months ago

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

Jul 22, 2025, 2:56 PM EDT - 5 months ago

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Jul 22, 2025, 11:03 AM EDT - 5 months ago

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 11, 2025, 4:01 PM EDT - 5 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2025, 10:00 AM EDT - 7 months ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 7 months ago

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

May 22, 2025, 11:19 AM EDT - 7 months ago

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

May 22, 2025, 7:00 AM EDT - 7 months ago

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

May 16, 2025, 8:00 AM EDT - 7 months ago

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025, 4:01 PM EDT - 8 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

May 8, 2025, 5:00 AM EDT - 8 months ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

COYA

UgoGreg
UgoGreg Dec. 21 at 9:04 PM
$REPL https://stocktwits.com/symbol/CRDF
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Dec. 19 at 4:06 PM
$REPL pdufa in several months but the market super competitive for melanoma
0 · Reply
Doplrshift
Doplrshift Dec. 16 at 9:00 PM
$REPL this one might be in for a massive drop after that close
0 · Reply
Doplrshift
Doplrshift Dec. 16 at 8:55 PM
$REPL is this the lowest close for this stock since before thanksgiving
0 · Reply
Doplrshift
Doplrshift Dec. 16 at 8:51 PM
$REPL and so is the stock today
0 · Reply
BigTree79
BigTree79 Dec. 16 at 12:26 PM
$REPL wow this board is dead
0 · Reply
ItTakesItAll
ItTakesItAll Dec. 9 at 1:32 PM
$REPL 280%+ 2.79-10.73🎈 The ultimate 6-month ROI? Last July, I spotted and capitalized on a perfect market distortion from an overreaction. That generated a stunning 185%+ ROI by July 2025, a growth story still flourishing six months later. Stop accepting the norm, break free, block out the noise, and genuinely live.
1 · Reply
Dorps332
Dorps332 Dec. 8 at 2:45 PM
$IOVA guess it’s better to have a non approved treatment like $REPL then to have a working approved treatment like ourself
2 · Reply
Stock_Catcher
Stock_Catcher Dec. 5 at 3:44 AM
Fortune Friday Watchlist Pt. 10 $ETHZ $HUBC $REPL $JFBR $PTN Let's Bank Tomorrow ✅
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 4 at 4:48 PM
$REPL Share Price: $10.47 Contract Selected: Dec 26, 2025 $10 Calls Buy Zone: $0.47 – $0.58 Target Zone: $0.87 – $1.06 Potential Upside: 76% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Nbclean
Nbclean Dec. 3 at 9:26 PM
$REPL when is the next news due?
0 · Reply
tttggg
tttggg Dec. 3 at 5:21 PM
$CAPR I cannot imagine how humiliated / bitter Prasad must feel right now… he literally put Verdun on leave for her objection to cancel the adcomm… Verdun would be 100x more qualified as the head of CBER!!! Prasad is a joke… anyway, I believe $QURE $REPL will benefit from the positive hope3 result as well.
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 3 at 3:08 AM
Winner Wednesday Watchlist Pt. 10 $ACON $REPL $BLMZ $CAPR $RGTI Let's Bank Tomorrow 📈🎯
0 · Reply
JFais
JFais Dec. 3 at 2:16 AM
$REPL (NP) From today's trades
0 · Reply
RunnerSignals
RunnerSignals Dec. 2 at 9:30 PM
Red? Just a warm-up 😏 $AG $REPL $AREC $NAT $PUMP.X dipped like they were quitting but closed with swagger
0 · Reply
dixiebull
dixiebull Dec. 2 at 7:22 PM
*$LCID $REPL $SOC $WEN $WOLF
1 · Reply
meatpuppets
meatpuppets Dec. 2 at 5:01 PM
$LUNG $PLUG $REPL $UPXI they would rather pay 2.00 for the lung 🫁
0 · Reply
Dorps332
Dorps332 Dec. 2 at 4:37 PM
$REPL this pump is all to the FDA Pazdur set to retire?
1 · Reply
TheRoaringMitty
TheRoaringMitty Dec. 2 at 4:24 PM
$REPL whats happening? latest news?
1 · Reply
Stock_Catcher
Stock_Catcher Dec. 2 at 4:19 PM
$REPL vol
0 · Reply
lucinith
lucinith Dec. 2 at 5:50 AM
$REPL take a look at $OTLK. Thank me later.
0 · Reply
JFais
JFais Nov. 29 at 8:52 PM
$REPL (L) From Weekly Recap
1 · Reply